These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Furthermore, nasal anti-CD3 dampens cytotoxic CD8 T cell responses shown to cause lung damage in COVID-19. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Telstra Corp Ltd (ASX: TLS) Share Price and News. Pursuant to AIM Rule 41 of the AIM Rules for Companies, the Company hereby gives notice of the intended cancellation of trading of its Ordinary Shares on the AIM market of the London Stock Exchange ("AIM").Admission will be through an introduction of the existing Ordinary Shares. Tiziana Life Sciences PLC (TILS:LSE) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of hospitalized COVID-19 patients with severe respiratory symptoms.For further enquiries:United Kingdom:  Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder+44 (0)20 7495 2379 Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner +44 (0)20 7213 0880 Optiva Securities Limited (Broker) Robert Emmet \+ 44 (0)20 3981 4173 United States: Investors Dave Gentry, CEO RedChip Companies Inc. 407-491-4498 dave@redchip.com, NEW YORK and LONDON, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announced that an interview with its CEO and CSO Dr. Kunwar Shailubhai is now available. (See TLSA stock analysis on TipRanks).Related News: Pfizer Inks Deal To Manufacture Gilead’s Covid-19 Remdesivir Treatment Krystal’s ‘Promising’ Cystic Fibrosis Drug Scores Orphan Designation Gilead ‘Very Pleased’ With Tango Collab, Boosts Cancer Targets To 15 More recent articles from Smarter Analyst: * American Express To Acquire Online Lender Kabbage * Susquehanna Lifts Nvidia’s PT To ‘Street High’ Ahead of Tomorrow's 2Q Results * Home Depot Sales Exceed Estimates As Shoppers Pile On DIY Products * Hilton vs Marriott: Which Hotel Stock Is Best Poised For Recovery? Check out why TIL Ltd share price is falling today. J Clin Invest 2020; 130: 2620–2629. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn’s Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. In a humanized mouse model (NOD/SCID IL2γc-/-), it was shown that while targeting the T cell receptor, orally administered Foralumab modulates immune responses of the T cells, enhances Tregs and thus provides therapeutic benefit in treating inflammatory and autoimmune diseases without the occurrence of potential adverse events usually associated with parenteral mAb therapy (Ogura M. et al., 2017). This indicates shares can surge a further 188% from current levels.“We note that our current valuation does not include any contribution from the use of Foralumab to treat COVID-19-infected patients. GB00BKWNZY55. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn’s Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.For further enquiries: United Kingdom:Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder+44 (0)20 7495 2379 Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner+44 (0)20 7213 0880 Optiva Securities Limited (Broker) Robert Emmet\+ 44 (0)20 3981 4173 United States: Investors Dave Gentry RedChip Companies Inc. 407-491-4498 Dave@redchip.com, -          Dr. Ferrara is the discoverer of Avastin® and Lucentis®, multi-billion dollars antibody drugs from Genentech -          A member of National Academy of Sciences and recipient of several prestigious awards, including the Lasker award. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.Forward-Looking Statements Certain statements made in this announcement are forward-looking statements. In addition to milciclib, the Company will be shortly initiating phase 2 studies with orally administered foralumab for Crohn’s Disease and nasally administered foralumab for progressive multiple sclerosis. Based upon the Related Parties' shareholding in the Company as at the date of this document, upon completion of the Demerger, the Related Parties will have the following holdings in each of the Company and Accustem: Current holding of Tiziana Shares% of current holding of Tiziana SharesExpected % of issued share capital of the Company following the DemergerExpected % of issued share capital of Accustem following the Demerger Panetta Partners Limited691,5210.36%691,5210.36% Planwise Group Limited63,680,40433.42%63,680,40433.42% Dr Kunwar Shailubhai5,0000.002%5,0000.002% Note: the above figures assume no changes to the underlying holdings of the named shareholders after publication of this document and before the Record Date.Willy Simon and John Brancaccio are deemed to be independent of the Demerger for the purposes of Rule 13 of the AIM Rules. 10,758,541 (Inventor: Kunwar Shailubhai). Mining is big business, Here are a few things that you should know before adding mining stocks to your port.... LONDON and NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces it has applied to list its ordinary shares ("Ordinary Shares") on the standard listing segment of the Official List of the Financial Conduct Authority (“FCA”) (the "Official List") and admission to trading on the London Stock Exchange plc's (the "London Stock Exchange") main market ("Main Market") for listed securities (together, "Admission"). The person who arranged for the release of this announcement on behalf of the Company was Keeren Shah, Finance Director of the Company.About Tiziana Life SciencesTiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIM: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation, and infectious diseases. Additionally, oral capsules provide the convenience of home use, and increase patient compliance by eliminating the need for infusions in a clinic or hospital setting.“The prevalence of inflammatory bowel disease is rising globally, imposing a significant burden both on patients as well as healthcare systems worldwide,” said Sy Pretorius, MD, Parexel Executive Vice President and Chief Medical & Scientific Officer. The poster on Phase 2a clinical evaluation of Milciclib, a broad-spectrum inhibitor of cyclin dependent kinases, indicated that the treatment was well-tolerated, and it produced encouraging clinical activity in sorafenib-resistant patients of HCC(1). When the traded price is any other currency then the Trade Value is displayed in that currency. This scientific advancement provides the basis to move forward with clinical development of nasally administered Foralumab in COVID-19 disease.” He continued, “My colleague Dr. Thais Moreira worked very closely with clinicians at the Brazilian hospital and the team at the INTRIALS to expedite this highly innovative first-in-class study for treating COVID-19 disease.”Dr. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.For further enquiries:United Kingdom Investors:Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379    Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner +44 (0)20 7213 0880    Optiva Securities Limited (Broker) Robert Emmet \+ 44 (0)20 3981 4173 United States Investors:Dave Gentry RedChip Companies Inc. Office 1 800 RED CHIP (733 2447) Cell 407-491-4498 (USA) dave@redchip.com, Tiziana Life Sciences (TLSA) has announced that it has begun a collaborative clinical study investigating nasally administered Foralumab either alone or in combination with orally administered dexamethasone in COVID-19 patients in Brazil.Scientific teams at the Harvard Medical School, Santa Casa de Misericórdia de Santos Hospital and at Tiziana are closely collaborating to facilitate initiation of this study in expedited time frames, the company says.The study will start dosing patients on November 3, with clinical data expected before the end of 2020.“Brazil is now experiencing almost 1000 deaths per day. B., Moran, C. J., McCann, K., Dunn, W. A., Farraye, F. A., Ananthakrishnan, A. N., Yajnik, V., Gandhi, R., Nguyen, D. D., Bhan, A. K., Weiner, H. L., Korzenik, J. R., and Snapper, S. B. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.Forward-Looking Statements Certain statements made in this announcement are forward-looking statements. However, for technical reasons, the ADR Record Date can only be established at a later date. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. In a phase I study, oral treatment with Milciclib was found to be well-tolerated and the drug showed promising clinical responses in patients with advanced solid malignancies such as in NSCLC, pancreatic and colon cancer, thymic carcinoma and thymoma. “We’re excited to be collaborating with Tiziana to support the development of a novel, oral therapy that could provide Crohn’s patients with another option in their repertoire of treatments to combat this devastating disease.”Recently, Tiziana announced positive results from its Phase 1 study showing that oral treatment with Foralumab was well-tolerated in healthy volunteers, with no drug-related safety issues even at the highest dose of 5 mg2. Tiziana Life Sciences January 9, 2020 Press Release (https://ir.tizianalifesciences.com/news-releases/news-release-details/tiziana-life-sci-plc-further-re-foralumab-phase-1-trial)3\. Methods and use of anti-IL-6/IL-6 receptor monoclonal antibodies as prophylactic and therapeutic interventions for human diseases, including COVID-19 and other pulmonary diseases 3. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. In addition to milciclib, the Company will be shortly initiating Phase 2 studies with orally administered Foralumab for Crohn’s Disease and nasally administered Foralumab for progressive multiple sclerosis. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Thus, we are now fulfilling our promise to shareholders to demerge the asset and create a new public company that will focus exclusively on the commercialization of StemPrintER. Like most human cancers, HCC is a complex multi-factorial cancer with multiple underlying mechanisms causing enormous heterogeneity in patient populations. We believe switching to oral, nasal and inhalational administration of mAbs from the traditional intravenous administration could potentially be transformational for the future development of immunotherapies.”This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. For example, COVID-19 patients often develop an uncontrolled immune response (“cytokine storm”) resulting in severe damage to the lung tissue which could lead to respiratory failure. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Willy Simon, John Brancaccio and Dr Kunwar Shailubhai, having consulted with the Company’s nominated adviser, Cairn Financial Advisers LLP, consider that the terms of the Demerger referred to above are fair and reasonable in so far as the Tiziana Shareholders are concerned.NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. TIL Share Price, TIL Stock Price, TIL Ltd. Stock/Share prices, TIL Ltd. Live BSE/NSE, F&O Quote of TIL Ltd. with Historic price charts for NSE / BSE. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Clin Immunol 183, 240-2465\. The proposed demerger, which requires a court-approved reduction of capital to be completed, will allow Accustem to continue the commercialisation efforts of the StemPrintER platform technology as a separate listed company with cash reserves of approximately £1.0 million. Thus, there is an urgent need for combination drug treatment approaches targeting different mechanisms to achieve better clinical outcomes. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.For further enquiries:United Kingdom:Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner +44 (0)20 7213 0880 Optiva Securities Limited (Broker) Robert Emmet +44 (0)20 3981 4173United States:Investors Dave Gentry, CEO RedChip Companies Inc. 407-491-4498 dave@redchip.com, Proposed capital reduction and notice of General MeetingLONDON, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Plc (LSE: TILS, NASDAQ: TLSA) a biotechnology company focussed on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that, following a strategic review of its clinical trial programs and core focus, it intends to demerge its StemPrintER and SPARE genomics-based personalised medicine business into a separate and independent listed company, Accustem Sciences Limited. This distinctive feature of TZLS-501, a fully human anti-IL-6R mAb, makes it potentially suitable for treatment of COVID-19 and ARDS.For example, COVID-19 patients often develop an uncontrolled immune response (“cytokine storm”) resulting in severe damage to the lung tissue which could lead to respiratory failure. Pivetti, A., Di Marco, L., Bristot, L., Milosa, F., Maria Critelli, R., De Maria, N., Di Benedetto, F., Palejwala, V., Jacob, J., Shailubhai, K., and Villa, E. (2020) Safety and Clinical Activity of Combination Treatment with Regorafenib and Milciclib in Liver Transplant Patients with Hepatocellular Carcinoma Recurrence. da Cunha, A. P., and Weiner, H. L. (2012) Induction of immunological tolerance by oral anti-CD3. It is not uncommon to see companies perform well in the years after insiders buy shares. BKWNZY5. CDKs are serine threonine kinases that play crucial roles in progression of the cell cycle from G1 to S phase. The Board has taken this decision as it believes that a standard listing will afford Tiziana greater flexibility in pursuing its strategy as an international company. Huang C, Wang Y, Li X, et al. Summary Live Market News Shares Comment Trades Director Deals Fundamentals Historic Prices. In addition to milciclib, the Company will be shortly initiating phase 2 studies with orally administered foralumab for Crohn’s disease and nasally administered foralumab for progressive multiple sclerosis. View live TIZIANA LIFE SCIENCES PLC ORD 3P chart to track its stock's price action. View the latest Tiziana Life Sciences (TILS) share price and news, including recent trades, historical charts, broker views and our views. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. To effect the demerger, Tiziana plans to distribute a 1:1 share dividend to its shareholders with a record date of 0700 London time on October 30, 2020.Accustem Sciences will begin the process of seeking CE Mark approval in November of 2020 with anticipated commercialization in Europe in the second quarter of 2021. Many studies have also indicated excessive levels of IL-6 in the lungs and in the blood of these patients, and it is believed that the cytokine storm in lungs is primarily due to excessive levels of IL-6.As a result, direct inhalation delivery of TZLS-501 to the lungs has the potential to deplete circulating levels of IL-6 and inhibit IL-6R signaling, providing immediate relief to COVID-19 patients, says the company.Year-to-date the stock has rallied an incredible 260%- and HC Wainwright analyst Ram Selvaraju is bullish on Tiziana’s outlook. Over the past few months, an increasing number of ordinary shares have been exchanged for ADSs. ET) and the After Hours Market (4:00-8:00 p.m. J Clin Invest 2020; 130: 2620–2629. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ’seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. It's a home security system that's built for the unexpected like downed wifi, cut landlines, power outage, hammers, and everything in between. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. The Accustem ADRs will be distributed to the holders of Tiziana ADRs as of the Record Date as and when the registration statements become effective. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn's Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. In view of the importance and urgency to develop an effective therapy for COVID-19 immediately, our Tiziana Life Sciences team, scientists at the Harvard Medical School and the scientific team at Santa Casa de Misericórdia de Santos Hospital (Jabaquara, Santos, Brazil) are working very quickly to start this clinical study in the next few weeks such that clinical data could be available before the end of this year,” commented Dr. Shailubhai, CEO and CSO of Tiziana Life Sciences.THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014The person who arranged for the release of this announcement on behalf of the Company was Dr. Kunwar Shailubhai, Chief Executive Officer and Chief Scientific Officer of the Company.Cited References 1.